Advocacy engagement: policy and public affairs Our policy priorities Creating a sustainable funding model for research in universities Encouraging international talent to support cancer research ...

As we enter 2026, scientists at The Institute of Cancer Research, London, share the developments expected this year that could soon change how cancer is treated – from technologies designed to deliver ...

As we enter 2026, scientists at The Institute of Cancer Research, London, share the developments expected this year that could soon change how cancer is treated – from technologies designed to deliver ...

Work with the Institute of Cancer Research and help people with cancer. Enquire about trusts and foundations today.

PENELOPE B is a phase III international, multicentre, randomised, placebo-controlled, double-blind trial comparing the efficacy and safety of adding palbociclib to standard hormone therapy vs standard ...

The Institute of Cancer Research, London, welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the targeted drug talazoparib (trade name Talzenna), in ...

Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.

We were the first in Europe to develop chemotherapeutic agents, and we discovered, and with The Royal Marsden NHS Foundation Trust developed, the chemotherapy drugs busulfan, chlorambucil, melphalan ...

A blood test can predict how well patients with advanced breast cancer will respond to targeted therapies – before treatment begins, according to new research. A team from The Institute of Cancer ...

What is this study about? FAST-Forward Boost investigates whether radiotherapy to treat breast cancer can be given in fewer treatment visits. Radiotherapy is the use of radiation to treat cancer.